MindWalk advances AI-designed GLP-1 therapeutics program

MindWalk (HYFT) announced a major advancement of its AI-designed GLP-1 therapeutics program. New insights from the company’s LensAI platform reveal a previously unrecognized connection between GLP-1 biology and a second, non-overlapping pathway central to healthy aging and systemic resilience. The findings support a first-in-class dual-pathway regimen in which MindWalk’s proprietary companion therapeutic is co-administered with its GLP-1 receptor agonists to engage both mechanisms in concert. To the company’s knowledge, no approved or marketed drugs use this regimen. The companion therapeutic is a MindWalk-exclusive asset and is not a repurposed or co-branded product. “GLP-1 drugs have already transformed diabetes and obesity care, but their potential as Healthspan medicines is only beginning to be recognized,” said Jennifer Bath, CEO of MindWalk. “By applying HYFT and LensAI, we are not simply iterating on existing drugs-we are uncovering first principles that enable the design of safe, durable GLP-1 analogs and a proprietary companion therapeutic that acts through a complementary longevity pathway. To our knowledge, this represents a new route in longevity medicine and a direct evolution of our earlier success, showing how our Bio-Native AI platform creates repeatable, high-impact programs in preventive health.”